cpt1

Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a) (IC50=5-20 nM). Etomoxir inhibits fatty acid oxidation by inhibiting CPT-1a, inhibits palmitate oxidation, has an inhibitory effect on adenine nucleotide translocase, and can inhibit macrophage polarization by disrupting CoA homeostasis.

McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor used for researching metabolic diseases.

Teglicar is a selective and reversible inhibitor of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1).

CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).

Perhexiline maleate is an orally active inhibitor of CPT1 and CPT2, reducing fatty acid metabolism, with IC50 values of 77 μM and 148 μM against rat heart and liver CPT1, respectively.

Etomoxir sodium salt ((R)-Etomoxir sodium salt) is a carnitine palmitoyltransferase 1a (CPT-1a) inhibitor that inhibits fatty acid oxidation (FAO). Etomoxir sodium salt has antitumor activity.

Irinotecan hydrochloride trihydrate (CPT-11 HCl Trihydrate) keeps DNA from unwinding by inhibiting topoisomerase 1.

Irinotecan Hydrochloride (CPT-11 hydrochloride) is the hydrochloride salt of a semisynthetic derivative of camptothecin. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.

Irinotecan (CPT-11), a derivative of camptothecin, is an inhibitor of DNA topoisomerase I (Topo I). Irinotecan has antitumor activity by preventing DNA strand reattachment through binding to the Topo I complex, resulting in double-stranded DNA breaks and cell death.

CPT-157633 is a difluoro-phosphonomethyl phenylalanine derivative that acts as a potent inhibitor of the enzyme PTP1B. It effectively prevents the development of glucose intolerance induced by binge drinking.

C75 is a fatty acid synthase (FASN) inhibitor (IC50 = 35 μM in PC3 cells) with cell permeability and the ability to activate CPT1A. This compound possesses antitumor activity and is commonly used in cancer-related experimental research.

Teglicar (also known as ST1326) is a selective reversible inhibitor of carnitine palmitoyltransferase 1 (L-CPT1), the liver isoform. It reduces ketogenesis and glucose production, decreases gluconeogenesis, and enhances glucose homeostasis.

Perhexiline is an orally active inhibitor of CPT1 and CPT2 that reduces fatty acid metabolism. Perhexiline can cross the blood-brain barrier (BBB) and exhibits anti-tumor activity. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatocytes. Therefore, Perhexiline can be used in cancer and cardiovascular disease research [1] [2] [5].

S-(-)-Etomoxir is an inhibitor of carnitine palmitoyltransferase A (CPT1) -- a molecule required for the oxidation of long-chain acyl CoA esters.

Malonyl CoA serves as a substrate in fatty acid biosynthesis while inhibiting fatty acid oxidation. It also acts as a reversible inhibitor of mitochondrial carnitine palmitoyltransferase (CPT) 1 [1] [2].

4-Hydroxyphenylglyoxylic acid, an active metabolite of the prodrug oxfenicine, functions as an inhibitor of carnitine palmitoyltransferase 1 (CPT1). It effectively inhibits CPT1 in isolated rat liver mitochondria at concentrations of 200 to 1,000 µM and restricts oleate oxidation in isolated rat hepatocytes.